{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020841","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.983633+00:00","generated_at":"2026-06-15T04:44:32.838344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023","bullets":["Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.","Cash, cash equivalents, and marketable securities of $197.2M as of March 31, 2023; expected to fund operations to early 2026.","36-week data from Phase 2b ORIGIN trial of atacicept in IgAN selected as late-breaking presentation at ERA Congress 2023.","Plan to initiate pivotal Phase 3 trial of atacicept in IgAN in Q2 2023.","Appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020841","json":"https://secwatch.observer/filing/0000950170-23-020841.json","markdown":"https://secwatch.observer/filing/0000950170-23-020841.md","text":"https://secwatch.observer/filing/0000950170-23-020841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/0000950170-23-020841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/vera-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:44:32.838344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a43ae2a5ddb398ddc498539ffa91613436c352b2","claim":"Vera Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income net loss of $30.1 million, EPS net loss per diluted share of $0.80.","evidence_excerpt":"For the quarter ended March 31, 2023, the company reported a net loss of $30.1 million, or a net loss per diluted share of $0.80","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/0000950170-23-020841-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $30.1 million"},{"label":"EPS","value":"net loss per diluted share of $0.80"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}